Redsense Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Redsense Medical şirketinin toplam hissedar öz sermayesi SEK30.2M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK34.4M ve SEK4.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 8.12m
Eşitlik	SEK 30.16m
Toplam yükümlülükler	SEK 4.23m
Toplam varlıklar	SEK 34.38m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why We're Watching Redsense Medical's (NGM:REDS) Cash Burn Situation

Jun 15

Redsense Medical (NGM:REDS) Is In A Good Position To Deliver On Growth Plans

Mar 01

We're Not Very Worried About Redsense Medical's (NGM:REDS) Cash Burn Rate

Nov 10

Is Redsense Medical (NGM:REDS) In A Good Position To Deliver On Growth Plans?

Apr 20

Shareholders Are Thrilled That The Redsense Medical (NGM:REDS) Share Price Increased 236%

Feb 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: REDS 'nin kısa vadeli varlıkları ( SEK20.5M ) kısa vadeli yükümlülüklerini ( SEK4.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: REDS 'un kısa vadeli varlıkları ( SEK20.5M ) uzun vadeli yükümlülüklerini ( SEK-1,000.0 ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: REDS borçsuzdur.

Borcun Azaltılması: REDS şirketinin 5 yıl önce borç/öz sermaye oranı 231% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: REDS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: REDS un, serbest nakit akışı her yıl % 7.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Redsense Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching Redsense Medical's (NGM:REDS) Cash Burn Situation

Redsense Medical (NGM:REDS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Redsense Medical's (NGM:REDS) Cash Burn Rate

Is Redsense Medical (NGM:REDS) In A Good Position To Deliver On Growth Plans?

Recent updates

Redsense Medical AB (publ) to Report Q3, 2024 Results on Nov 26, 2024

New major risk - Market cap size

Redsense Medical AB (publ) Announces Board Changes

Second quarter 2024 earnings released

Redsense Medical AB (publ) to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Shareholder dilution

Redsense Medical AB Announces CEO Changes

First quarter 2024 earnings released

Full year 2023 earnings released: kr0.32 loss per share (vs kr0.62 loss in FY 2022)

Redsense Medical AB (publ) to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: kr0.32 loss per share (vs kr0.62 loss in FY 2022)

New minor risk - Share price stability

Redsense Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Less than half of directors are independent

Redsense Medical Appoints Eva Walde as Chairman of Board of Directors

Third quarter 2023 earnings released

Redsense Medical AB (publ), Annual General Meeting, May 08, 2024

Redsense Medical AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings released

New minor risk - Share price stability

Redsense Medical AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

First quarter 2023 earnings released

Redsense Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 27, 2023

Redsense Medical AB (Publ) Announces Appointment of Jennie Kardell as Chief Financial Officer, Effective March 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released

Redsense Medical AB (Publ) Appoints Patrik Byhmer as Chairman of the Board

Here's Why We're Watching Redsense Medical's (NGM:REDS) Cash Burn Situation

Forecast breakeven date pushed back to 2024

First quarter 2022 earnings: Revenues miss analyst expectations

Redsense Medical AB (Publ) Appoints Pontus Nobréusis as CEO

Price target decreased to kr27.50

Less than half of directors are independent

Redsense Medical AB (publ), Annual General Meeting, May 02, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Redsense Medical (NGM:REDS) Is In A Good Position To Deliver On Growth Plans

Director recently bought kr62k worth of stock

We're Not Very Worried About Redsense Medical's (NGM:REDS) Cash Burn Rate

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Less than half of directors are independent

Price target decreased to kr66.00

Redsense Medical Receives TGA Approval and Market Authorization for Australia and New Zealand

Redsense Medical AB (publ) Provides Update About Sales Guidance for the First Half of 2021

Is Redsense Medical (NGM:REDS) In A Good Position To Deliver On Growth Plans?

Shareholders Are Thrilled That The Redsense Medical (NGM:REDS) Share Price Increased 236%

Full year 2020 earnings released: kr0.70 loss per share (vs kr0.42 loss in FY 2019)

New 90-day low: kr40.20

New 90-day low: kr42.60

Redsense Concludes Development Project Related to AI-Driven Wound Monitoring Software

New 90-day high - kr44.20

Earnings released

New 90-day high - kr39.20

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin